A Phase I/II Study of Natalizumab as a Single Agent in Children, Adolescents and Young Adults With Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

The purpose of this study is to evaluate the safety and tolerability of Natalizumab in children, adolescent and young adult patients with pulmonary metastatic osteosarcoma (pOS) and to assess clinical response associated with this treatment as well as overall survival.

Start Date01 Dec 2024

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT05658497

/ RecruitingNot Applicable

Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and, ii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries).
The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).

Start Date27 Oct 2023

Sponsor / Collaborator

Biogen, Inc.

NCT05618301

/ CompletedPhase 1IIT

A Pilot Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Hematopoietic stem cell (HSC)-based gene therapies now offer curative potential for patients with sickle cell disease (SCD), with decreased toxicity compared to allogeneic hematopoietic cell transplantation. However, effective HSC-based gene therapy depends on collecting sufficient HSCs to generate the therapeutic product, and currently available mobilization regimens carry unacceptable risk for patients with SCD or do not reliably yield optimal numbers of HSCs for gene therapy.
The investigators hypothesize that HSC mobilization with motixafortide (CXCR4i) alone and the combination of motixafortide plus natalizumab (VLA-4i) will be safe and tolerable in SCD patients. In addition, the investigators hypothesize that combined CXCR4 and VLA-4 blockade with motixafortide plus natalizumab will result in a rapid, robust, and synergistic increase in HSC mobilization to peripheral blood (PB) in patients with SCD, when compared to motixafortide alone.

Start Date07 Jul 2023

Sponsor / Collaborator

Washington University School of Medicine

[+2]

100 Clinical Results associated with Natalizumab

100 Translational Medicine associated with Natalizumab

100 Patents (Medical) associated with Natalizumab

3,112

Literatures (Medical) associated with Natalizumab

01 Sep 2025·Multiple Sclerosis and Related Disorders

Discontinuation of disease-modifying therapy in stable multiple sclerosis: A systematic review and meta-analysis

Review

Author: Shahid, Sufyan ; Khan, Mishal ; Hasan, Ahmedyar ; Qasim, Soban Ali ; Iqbal, Minahil ; Ayatullah, Omama ; Batool, Ayesha

BACKGROUND:

Disease-modifying therapies (DMTs) are used to manage multiple sclerosis (MS), particularly in individuals with relapse-onset MS, to slow disease progression, reduce inflammation and demyelination and improve quality of life. Discontinuing treatment may pose a greater relapse risk for younger individuals with active disease, whereas the safety of treatment cessation in older, stable patients remains uncertain.

METHODS:

We conducted a systematic review and meta-analysis of studies comparing discontinuation of disease-modifying therapy in stable multiple sclerosis patients. Data were collected from PubMed, Embase, and Cochrane Central databases. Statistical analysis was performed using Review Manager v5.4. A random-effects model was applied to pool risk ratios (RRs) and 95 % confidence intervals, with statistical significance set at p < 0.05.

RESULTS:

A total of eight studies, including 4517 patients (3355 in the continuation group and 1162 in the discontinuation group), were analyzed. The mean age of participants was 53 years, with 72.7 % being female. Discontinuation of disease-modifying therapy (DMT) in patients with stable multiple sclerosis (MS) was associated with a significantly higher risk of mild adverse events (RR 1.29; 95 % CI 1.15-1.46; p < 0.0001). However, the risk of relapse (RR 0.31; 95 % CI 0.03-3.21; p = 0.33), as well as moderate (RR 1.11; 95 % CI 0.97-1.28; p = 0.14) and severe adverse events (RR 0.90; 95 % CI 0.45-1.78; p = 0.75), was comparable between the two groups. Similarly, the risk of common or treatment-related adverse events, including COVID-19 (RR 0.65; 95 % CI 0.28-1.52; p = 0.32), influenza (RR 0.39; 95 % CI 0.14-1.08; p = 0.07), and abnormal white blood cell count (RR 1.03; 95 % CI 0.11-3.21; p = 9.77), did not differ significantly between the continuation and discontinuation groups.

CONCLUSION:

This meta-analysis found no significant increase in relapse risk after DMT discontinuation in stable MS patients. However, outcomes varied based on patient age, prior DMT, and duration of disease stability. Agents like S1P inhibitors and natalizumab may carry higher relapse risk after cessation. Additionally, new MRI lesions were noted in some studies, highlighting the need for continued monitoring. Treatment decisions should be individualized until further long-term data become available.

01 Sep 2025·Multiple Sclerosis and Related Disorders

Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study

Article

Author: Matos, Sara ; Batista, Sónia ; Nunes, Carla ; Bernardes, Catarina ; Campelo, Isabel ; Cardoso, João ; Carvalho, Inês ; Sousa, Lívia ; Macário, Carmo ; Correia, Inês ; Cunha, Carolina

BACKGROUND:

Natalizumab (NTZ) is a highly effective multiple sclerosis (MS) treatment but carries a high risk of progressive multifocal leukoencephalopathy in JCV-positive patients. Switching to other therapies is sometimes necessary despite the risk of increasing disease activity, even with other highly effective treatments, such as anti-CD20 therapies.

OBJECTIVE:

To evaluate anti-CD20 therapies effectiveness after NTZ discontinuation.

METHODS:

A retrospective study including MS patients who switched NTZ to anti-CD20 therapies: rituximab (RTX), ocrelizumab (OCR), and ofatumumab (OFA). Demographic, clinical, and safety data were analyzed.

RESULTS:

We included 59 patients (41 female). Mean disease duration at data collection was 7,88 ± 6,62 years. The main reason for NTZ discontinuation was safety concerns related to JCV seroconversion and serum titer increase (n = 52). RTX patients had significantly longer and more active disease before transition. Comparing annualized relapse rate (ARR) and EDSS before and after switch, RTX significantly reduced ARR (0,65 vs 0,08; p = 0007) but led to a significant EDSS increase (3,65 vs 4,15; p = 0022). No significant changes were observed for OCR and OFA. ARR reduction was greater with RTX than OCR and OFA (p = 0018), though EDSS variation did not differ. Survival analysis showed no difference in time to disease activity between groups. In this cohort, 70 % of disability progression was due to progression independent of relapse activity (PIRA).

CONCLUSION:

Anti-CD20 therapies appear to be a safe option after NTZ discontinuation, with no rebound disease and stable EDSS. PIRA was the main driver for disability progression, emphasizing the need to control smoldering disease.

08 Aug 2025·Deutsches Arzteblatt International

Treatment Options for the Comorbidity of Multiple Sclerosis With Other Chronic Inflammatory Diseases.

Review

Author: Bittner, Stefan ; Kümpfel, Tania ; Siegmund, Britta ; Sabat, Robert ; Kriegel, Martin A.

BACKGROUND:

Approximately 280 000 people in Germany suffer from multiple sclerosis (MS), an autoimmune disease of the central nervous system. Of these, approximately 5% have a comorbid chronic inflammatory disease: the more common ones are psoriasis, rheumatoid arthritis (RA), and chronic inflammatory bowel diseases (IBDs, of which the main types are ulcerative colitis and Crohn's disease).

METHODS:

This narrative review is based on pertinent publications retrieved by a literature search in PubMed, as well as relevant guidelines. All statements in this article reflect a consensus among the authors, who represent different medical disciplines.

RESULTS:

As the data from clinical trials to date are limited, judgments about the proposed treatments are a matter of expert opinion. In general, TNFα blockers should not be used in patients with MS, as they can worsen the disease. In patients with MS and psoriasis, dimethyl fumarate is a useful option for mild disease activity. In MS with comorbid RA, azathioprine and leflunomide/teriflunomide are suitable for mild disease activity. For more severe disease activity, anti-CD20 antibodies have been approved for both diseases and should be used. In MS with comorbid IBD, azathioprine is suitable for mild disease activity. Ozanimod has been approved for patients who have MS and comorbid ulcerative colitis with more severe disease activity, especially those who are JC-negative; it shares its mechanism of action (VLA-4 blockade) with natalizumab.

CONCLUSION:

The treatment of patients who have both MS and another chronic inflammatory disease should be interdisciplinary and personalized, and treatments must be planned with due attention to potential adverse effects. Further studies of treatment for this group of patients are needed.

180

News (Medical) associated with Natalizumab

21 Jul 2025

·www.biospace.com

Biogen Commits $2B To Expand US Drug Production Amid Tariff Talk

iStock, JHVEPhoto The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce drugs such as the ALS therapy Qalsody. Biogen unveiled a $2 billion investment in North Carolina on Monday, joining the list of biopharma companies that have moved to beef up their U.S. manufacturing capabilities amid the ongoing threat of tariffs from President Donald Trump. Multiple leading drugmakers committed to investing in U.S. manufacturing after Trump was elected for a second term and first began saying pharma-specific tariffs were coming. Most recently, Trump earlier this month threatened to impose tariffs of up to 200% on pharmaceutical imports but said companies will have at least one year to move to the U.S. Then he said such levies could come as soon as Aug. 1 . Novartis and others have warned the process of reshoring manufacturing operations will take three to four years. Of the Big Pharma U.S. manufacturing commitments made so far, North Carolina is among the main beneficiaries, with Johnson & Johnson, Merck, Regeneron and Roche all outlining plans to invest in the state. Biogen, which already has a big presence in the state, is on track to open its eighth plant in Research Triangle Park (RTP) there later this year. Looking beyond that milestone, Biogen plans to invest in multiple factories across its two campuses in RTP to expand its capabilities across a range of drug modalities over the next few years. Biogen said it will expand its antisense oligonucleotide capabilities and infrastructure and establish multi-platform fill-finish capabilities at clinical and commercial scales. The biotech will also continue to modernize its manufacturing technologies and controls, including by investing in advanced automation and artificial intelligence. Biogen said it has invested $10 billion to date in drug production in North Carolina, a state where it broke ground in 1995 and now employs 1,500 manufacturing and technical workers across two campuses. The investment tally includes $3 billion that the company said it has invested in recent years. Biogen began construction of its eighth RTP facility in 2021. The company is investing an estimated $195 million in the new 197,000-square-foot facility. However, Biogen has warned there is no guarantee that the plant will be fully used after it opens later this year. The facility was designed to produce gene therapies, create clinical packaging and perform other manufacturing tasks. After starting construction, Biogen refocused its investment in gene therapy. The pipeline prioritization led the company to start evaluating several alternative uses for the facility. Biogen produces Avonex, Plegridy, Tysabri and Qalsody at its existing RTP facilities. The company makes Qalsody at an oligonucleotide synthesis manufacturing facility that is equipped to produce clinical and commercial batches. Spinraza is joining the list of products made at the oligonucleotide facility this year. On the other hand, the company produces Leqembi and Tysabri at its large-scale biologics facility in Switzerland, making the drugs potentially vulnerable to tariffs.

OligonucleotideGene Therapy

04 Jul 2025

·www.globenewswire.com

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined Immuthera’s Scientific Advisory Board.Immuthera will continue expanding its Scientific Advisory Board over the coming months to build a truly world-class team.In collaboration with PolTREG and leading U.S. academic centers, Immuthera will be developing a pipeline of cutting-edge, clinically validated Treg cell therapies for autoimmune and neuroinflammatory diseases. 4 JULY 2025 - Immuthera, a pioneer in cell therapies for autoimmune diseases, and parent company, PolTREG (Warsaw Stock Exchange: PTG), are proud to highlight the exceptional caliber of the first three members of its Scientific Advisory Board (SAB)—a team whose collective expertise and groundbreaking achievements are shaping the future of diabetes and immunotherapy research. The support and guidance from these globally renowned scientists underscore Immuthera’s commitment to delivering innovative, safe, and effective therapies for patients worldwide. “The collective wisdom and leadership of Drs. Skyler, Schatz, and Steinman provide Immuthera and PolTREG with an unparalleled strategic advantage. Their guidance ensures that our research and clinical programs are aligned with the highest standards of scientific rigor and patient care. Immuthera plans on expanding our SAB over the next several months to build a truly world-class team that will guide our activities in the US and beyond. With their support, Immuthera is uniquely positioned to accelerate the development of transformative therapies for type 1 diabetes and other autoimmune diseases” - said Prof. Piotr Trzonkowski, CEO of Immuthera and PolTREG. Immuthera will be working closely with PolTREG, and US academic centers, to develop a pipeline of cutting edge and clinically validated Treg cell therapies for the treatment of autoimmune and neuroinflammatory diseases. “Regulatory T cells (Treg cells) play a crucial role in maintaining immune homeostasis. As such, Immuthera’s and PolTREG’s delivery of Tregs offers hope for curing or controlling autoimmune diseases, including type 1 diabetes” – said Dr. Desmond Schatz. "I am excited to provide advice as Immuthera and PolTREG test their exciting technology in the clinic" – add Dr. Lawrence Steinman. A Scientific Advisory Board of Visionaries: Unrivaled Leadership in Diabetes and Immunology Dr. Jay Skyler: Architect of Modern Diabetes Care Dr. Jay Skyler stands as one of the most influential figures in type 1 diabetes research. His visionary work has transformed patient care and set new standards for clinical excellence: Pioneering Intensive Insulin Therapy: Dr. Skyler’s development of patient self-monitoring and intensive insulin protocols revolutionized diabetes management, empowering millions to achieve better glycemic control.Leadership in Landmark Clinical Trials: As Chairman of the NIH-sponsored Diabetes Prevention Trial – Type 1 (DPT-1) and Type 1 Diabetes TrialNet, Dr. Skyler has overseen global efforts to prevent and delay the onset of type 1 diabetes.Trailblazer in Immune Intervention: He led the first NIH-funded studies using cyclosporine and monoclonal antibodies to preserve beta-cell function, paving the way for modern immune therapies.Editorial and Organizational Leadership: Founding Editor-in-Chief of Diabetes Care and past President of the American Diabetes Association, Dr. Skyler’s influence extends from laboratory to clinic, and from policy to patient advocacy.Recognition: His accolades include the Banting Medal for Service, the Distinction in Endocrinology Award, and the Mary Tyler Moore/S. Robert Levine Award from JDRF. Dr. Desmond Schatz: Champion of Prevention, Genetics, and Pediatric Care Dr. Desmond Schatz’s four-decade career has been dedicated to unraveling the mysteries of type 1 diabetes, particularly in children and adolescents: Pioneering Research: Dr. Schatz has led major NIH and JDRF-funded studies on the prediction, genetics, and immunopathogenesis of type 1 diabetes, including the TEDDY program for newborn genetic screening and the Human Islet Research Network (HIRN).Clinical Trial Leadership: As Principal Investigator for the University of Florida’s TrialNet Clinical Center and a founding member of DPT-1, Dr. Schatz has driven international efforts to prevent and manage type 1 diabetes.Mentorship and Advocacy: A prolific author with over 400 publications, Dr. Schatz is recognized for nurturing the next generation of diabetes researchers and clinicians.Honors: His distinguished service has been recognized with the Banting Medal, ISPAD Prize for Achievement, the George Eisenbarth Award, and the University of Florida College of Medicine Lifetime Achievement Award. Dr. Lawrence Steinman: Innovator in Neuroimmunology and Autoimmune Therapies Dr. Lawrence Steinman’s research has redefined the landscape of neuroimmunology and autoimmune disease treatment: Breakthrough Therapy Development: His work at Stanford University led to the creation of Natalizumab (Tysabri), the first approved monoclonal antibody for multiple sclerosis (MS), now a standard of care worldwide.Groundbreaking Discoveries: Dr. Steinman’s research unveiled the molecular link between Epstein-Barr virus and MS, earning him the 2023 Pioneer in Medicine Award.Expanding the Frontiers: His expertise in antigen-specific therapies and DNA vaccines spans MS, ALS, neuromyelitis optica, and type 1 diabetes.Recognition: Dr. Steinman is a recipient of the John Dystel Prize, the Charcot Prize for Lifetime Achievement, and is an elected member of both the US National Academy of Sciences and the National Academy of Medicine. About Immuthera: Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG’s Research and Development capabilities and asset pipeline along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. About PolTREG: PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies.

ImmunotherapyDrug ApprovalExecutive ChangeClinical StudyCell Therapy

02 Jul 2025

·www.fiercepharma.com

Sandoz, on a $1.1B investment spree in Slovenia, breaks ground at new $440M biosimilar plant

The biosimilar specialist expects to open the doors to its new Slovenian production plant by 2028. Generic and biosimilar specialist Sandoz is strengthening its footprint in Slovenia, pledging $440 million to set up a new biosimilar facility for sterile product manufacturing some 24 miles from the nation's largest airport. The project brings the company’s total planned and ongoing investments in the central European country to more than $1.1 billion.Construction has already kicked off at the new site in Brnik, Slovenia, marking the latest milestone in Sandoz’s plan to claim a “significant part of an unprecedented market opportunity,” the company said in a July 1 press release. Sandoz was referring to the estimated value of biosimilar patent expirations, which it expects to reach a whopping $222 billion over the next decade."Biosimilars is the fastest-growing segment of our pipeline as the need of patients and healthcare systems for these critical medicines continues to grow rapidly,” CEO Richard Saynor said in a statement. “As the global leader in the field, we are investing to meet rapidly growing patient demand.” To prepare for the biosimilar boom, Sandoz has already put down roots in Slovenia with a previously announced biosimilar drug substance production center in Lendava and a biosimilar development center in the country’s capital of Ljubljana. Those sites will complement the newest $440 million plant, which is expected to open its doors in 2028 and will focus on making injectables for Sandoz’s existing and upcoming array of biologic copycats. The new plant’s functions will span preparation, filling, assembly and packaging for the company's biosimilar portfolio, plus onsite quality control, Sandoz said. All told, the $1.1 billion in Slovenian commitments through 2029 helps “significantly expand” Sandoz’s biosimilar manufacturing capacity in Europe and makes the company Slovenia’s largest direct foreign investor, Saynor commented."Our investment in biomanufacturing in the heart of Europe marks another important milestone in building our own independent manufacturing network—one that enhances our control, resilience and agility across the global supply chain,” Sandoz's chief manufacturing and supply officer, Glenn Gerecke, added.According to Gerecke, Slovenia was chosen for the “strategic value” the country brings with its strong talent pool, central location and cost-competitive production. Sandoz has said it's mapping out its Slovenia investments in a bid to establish an “end-to-end leading European biosimilar hub." Sandoz, a Novartis spinout, is responsible for bringing to market the world’s first biosimilar in 2006 and has since stacked its biosimilar portfolio with copycats of AbbVie’s Humira, Johnson & Johnson’s Stelara and Biogen’s Tysabri, to name just a few. The company’s pipeline is populated by 28 biosimilars and roughly 450 generics, with a handful of upcoming launches set to grow that roster later this year, including that for copies of Amgen’s leading bone meds Prolia and Xgeva. Last year, Sandoz grew its revenues by 9% to $10.4 billion.

Biosimilar

100 Deals associated with Natalizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D06886	Natalizumab	L04AA23	DB00108

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Crohn Disease	United States	Biogen, Inc.	14 Jan 2008
Multiple Sclerosis, Relapsing-Remitting	European Union	Biogen Netherlands BV	27 Jun 2006
Multiple Sclerosis, Relapsing-Remitting	Iceland	Biogen Netherlands BV	27 Jun 2006
Multiple Sclerosis, Relapsing-Remitting	Liechtenstein	Biogen Netherlands BV	27 Jun 2006
Multiple Sclerosis, Relapsing-Remitting	Norway	Biogen Netherlands BV	27 Jun 2006
Multiple Sclerosis	United States	Biogen, Inc.	23 Nov 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis, Secondary Progressive	Phase 3	United States	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	Belgium	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	Canada	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	Czechia	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	Denmark	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	Finland	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	France	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	Germany	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	Ireland	Biogen, Inc.	13 Sep 2011
Multiple Sclerosis, Secondary Progressive	Phase 3	Israel	Biogen, Inc.	13 Sep 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P7-1.012 (AAN2025)	Not Applicable	Multiple Sclerosis First line	-	Natalizumab (NTZ)	nzjqysopdp(ayjfmtgspx) = ltoxmqchxc nylmyxpsly (gmbxcgbkhh ) View more	Positive	07 Apr 2025
				Ocrelizumab (OCR)	nzjqysopdp(ayjfmtgspx) = smjvvbcqnv nylmyxpsly (gmbxcgbkhh ) View more
P8-1.016 (AAN2025)	Not Applicable	Multiple Sclerosis anti-CD20s \| natalizumab	188	Anti-CD20 therapy (Ocrelizumab)	blulrxyefa(aarinxqkqm): rate ratio = 0.81 (95% CI, 0.48 - 1.36), P-Value = 0.42 View more	Positive	07 Apr 2025
				Natalizumab (TYSABRI)
NCT03689972 (NOVA, Pubmed \| Neurol Neuroimmunol Neuroinflamm)	Phase 3	Multiple Sclerosis, Relapsing-Remitting trough serum natalizumab concentration \| α4-integrin saturation	486	Natalizumab Q6W dosing	huhnuxunyd(xkiwhejbzj) = fjhtqtgfut peujdzeuzj (mohlvjlihd )	Positive	01 Nov 2024
				Natalizumab Q4W dosing	huhnuxunyd(xkiwhejbzj) = iogyazsxwg peujdzeuzj (mohlvjlihd )
EAN2024	Not Applicable	Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia	-	Natalizumab (Adult-Onset Multiple Sclerosis (AOMS))	ihwqwmbfij(gsfgmtxtbu) = htgongpwtv srrxgfxxpl (oiweeljjup )	-	28 Jun 2024
EAN2024	Not Applicable	Multiple Sclerosis	-	Intravenous Natalizumab	mooxjizneq(svaekbnefj) = xazcsknkdt kwohioxqsn (qdunxarxnf ) View more	-	28 Jun 2024
				Intravenous then Subcutaneous Natalizumab	mooxjizneq(svaekbnefj) = wswjmkmivn kwohioxqsn (qdunxarxnf ) View more
EAN2024	Not Applicable	Multiple Sclerosis OCBs \| IgG index	326	Natalizumab	ixtiooporx(preprnuvhl) = nrnsupexpg hkyyhjmyyq (aigkshjdhs, 4.48 - 36.36)	Positive	28 Jun 2024
Italian MS and Related Disorders Register (EAN2024)	Not Applicable	-	770	Natalizumab	qbrwrxrzkf(gcjizdjoaj): HR = 1.23 (95% CI, 0.57 - 2.66), P-Value = 0.60 View more	Positive	28 Jun 2024
				Ocrelizumab
AAN2024	Not Applicable	Leukoencephalopathy, Progressive Multifocal	-	Natalizumab Extended Interval Dosing (EID)	pybtffunzx(trbdbxktvc) = aezhxdmhvz jphusuiori (kppcwogknm ) View more	-	09 Apr 2024
				Every-4-week (Q4W) Dosing	pybtffunzx(trbdbxktvc) = bvqqpkofku jphusuiori (kppcwogknm ) View more
NCT00027300 (AFFIRM, Pubmed \| Mult Scler) Manual	Phase 3	Multiple Sclerosis, Relapsing-Remitting	-	Natalizumab	ejeluvltzo(jgvqovjzxz) = wysmkbphzg ojldapoczl (ivenewwwmm ) View more	Positive	12 Mar 2024
				placebo	-
ACTRIMS2024	Not Applicable	Multiple sclerosis relapse	69	Natalizumab	pscjyfkjka(tzrhirihet) = ojzbodouet pvejajgszf (nyywibjtgt ) View more	Positive	01 Mar 2024
				Ocrelizumab	pscjyfkjka(tzrhirihet) = tfjenvduux pvejajgszf (nyywibjtgt ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis